喵咪社区

Effective rabbit analgesia is challenging, and there are few studies available on the newer COX-2 selective NSAIDs, such as robenacoxib. This study aimed to establish the pharmacokinetics of oral and subcutaneous robenacoxib, describe its inhibitory actions on COX enzymes, and develop dosing, using six healthy New Zealand white rabbits. Pharmacokinetics were determined from plasma concentrations after oral administration of robenacoxib (0.83-0.96鈥塵g/kg) and also after subcutaneous administration (2聽mg/kg). The inhibitory actions of robenacoxib were evaluated by measuring plasma concentrations of thromboxane B (TBX ) and prostaglandin E (PGE ) as surrogate markers of cyclooxygenase enzyme isoform inhibition. The mean maximum concentration for oral and subcutaneous administration was 0.23鈥壩糶/ml and 5.82鈥壩糶/ml, respectively. Oral robenacoxib administration did not demonstrate a significant difference between any time point for PGE or TBX , though subcutaneous administration did for both. There was no significant difference in PGE or TBX concentrations at any time point when comparing subcutaneous versus oral routes. Although the results support that plasma robenacoxib exceeds the therapeutic levels compared to dogs and cats, there was little significance in the difference in the changes associated with COX-1 and COX-2 inhibition. Further studies are warranted to determine appropriate dosing, safety, and efficacy in rabbits.